AbbVie’s blood cancer combo therapy fails in late-stage study

Sept 29 (Reuters) – AbbVie (ABBV.N) said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening.

The combination of AbbVie’s Venclyxto and a steroid dexamethasone was being tested in patients with relapsed multiple myeloma who had received two or more prior treatments.

Multiple myeloma is a cancer that forms in a type of white blood cells called plasma cells.

Venclyxto is being jointly commercialized by AbbVie and Roche (ROG.S) unit Genentech in the U.S. and by AbbVie outside the country.

Our Standards: The Thomson Reuters Trust Principles.